Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Upgrade from Raymond James

Core Viewpoint - Regeneron Pharmaceuticals has received an "Outperform" rating upgrade from Raymond James, reflecting confidence in its future performance and an increased price target from $820 to $870 [1][5]. Financial Performance - Regeneron's recent Q4 2025 earnings call likely provided insights into key financial metrics such as revenue and profit margins, along with strategic plans and future expectations [2][5]. - The current stock price is $741.45, showing a slight decrease of 1.07% or $7.99, with trading volatility observed between $735.61 and $774.37 [3][5]. - Over the past year, the stock reached a high of $821.11 and a low of $476.49, indicating dynamic market performance [3]. Market Position - Regeneron has a market capitalization of approximately $76.58 billion, underscoring its significant presence in the biotechnology sector [4][5]. - The trading volume for the day is 1,313,119 shares on the NASDAQ exchange, reflecting active investor interest [4].